[Oncogenicity of 6-hydroxytestosterone, delta- 3,5 -cholestadiene-7-one and delta- 4 -cholestene-3,6-dione].
D000236:Adenoma / Q000139:chemically induced; D000731:Androstanes / Q000009:adverse effects*; D000818:Animals; D002273:Carcinogens; D002776:Cholestanes / Q000009:adverse effects*; D005260:Female; D005354:Fibrosarcoma / Q000139:chemically induced*; D007942:Leukemia, Experimental / Q000139:chemically induced; D008175:Lung Neoplasms / Q000139:chemically induced*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000139:chemically induced; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009374:Neoplasms, Experimental / Q000139:chemically induced; D010954:Plasmacytoma / Q000139:chemically induced; D012513:Sarcoma, Experimental / Q000139:chemically induced; D012737:Sex Factors; D013261:Sterols; D013739:Testosterone / Q000009:adverse effects*
D000731:Androstanes; D002273:Carcinogens; D002776:Cholestanes; D013261:Sterols; D013739:Testosterone
Zur Onkogenität von 6-Hydroxytestosteron, delta 3,5 -Cholestadien-7-on und delta 4 -Cholesten-3,6-dion.